IDF Diabetes Atlas 10th Edition 2021

The IDF Diabetes Atlas 10th edition provides detailed information on the estimated and projected prevalence of diabetes, globally, by region, country and territory, for 2021, 2030 and 2045. It draws attention to the growing impact of diabetes across the world and highlights proven and effective actions that governments and policy-makers must urgently take to tackle it.

IDF Guide for Diabetes Epidemiology Studies

The IDF Guide for Diabetes Epidemiology Studies has been developed to create standardised epidemiological methods in diabetes studies. It will enable researchers to conduct high-quality studies that generate robust data, thereby providing the information needed to develop evidence-based strategies for improving care and strengthening healthcare systems.

IDF Diabetes Atlas Ninth Edition 2019

The IDF Diabetes Atlas is the authoritative resource on the global impact of diabetes. First published in 2000, it is produced by the International Diabetes Federation (IDF) in collaboration with a committee of scientific experts from around the world and contains statistics on diabetes prevalence, diabetes-related mortality and health expenditure at the global, regional and national level. The latest data published in the IDF Diabetes Atlas 9th edition shows that 463 million adults are currently living with diabetes.

Print copy orders

Due to the precautionary measures implemented in response to the COVID-19 outbreak, no print orders will dispatched between 13 March and 3 April 2020.

Taking Diabetes to Heart Report

Taking Diabetes to Heart is a multi-country study, developed by the International Diabetes Federation (IDF) in partnership with Novo Nordisk, focused on CVD awareness and knowledge among people living with type 2 diabetes. The study - the first of its kind in the world - builds on the IDF global report on Diabetes and Cardiovascular Disease (2016), which includes recommendations to reduce the burden of CVD among people with diabetes and the general population.

The aim of Taking Diabetes to Heart is to define the actions that are required to promote knowledge and awareness of cardiovascular disease among people living with type 2 diabetes, to improve their health outcomes and address systemic challenges to healthcare systems.

Cost-effective solutions for the prevention of type 2 diabetes

Despite the alarming statistics, cost-effective solutions exist to reduce the global burden that diabetes currently poses. Much can be done to prevent the onset of type 2 diabetes, as outlined in the IDF Cost-effective solutions for the prevention of type 2 diabetes report, which provides an overview of the latest evidence on the different programmes available to tackle the rise of the most prevalent form of diabetes. The wide range of options presented and their cost-saving implications give cause for optimism that the current situation can be reversed.

Global survey on Access to Medicines and Supplies for People with Diabetes

In 2016, IDF conducted a global survey on the perspective of people with diabetes and health professionals on Access to Medicines and Supplies for People with Diabetes. The report of the findings introduces diabetes and related medicines, provides the perception of people with diabetes, and health professionals on the availability, access and prices of medicines and supplies from around the world, and outlines public health policy solutions.

World Guide to IDF BRIDGES

The 2015 edition of the World Guide to BRIDGES aims to help investigators and community leaders from around the world learn about the experiences from the teams who led diabetes prevention and treatment projects supported by BRIDGES. In this publication, you will discover the challenges they faced, how they overcame them and discover practical advice to develop your own programme.

Diabetic Retinopathy Barometer

The Diabetic Retinopathy Barometer is the product of unique collaboration of experts from the International Federation on Ageing (IFA), International Diabetes Federation (IDF), International Agency for the Prevention of Blindness (IAPB), supported by Bayer Pharma AG. It is a study of almost 7,000 adults with diabetes and health care professionals from 41 countries – highlights the urgent need for clear patient care pathways and robust, responsive health systems around the world to prevent unnecessary vision loss associated with diabetes.

Diabetes and Cardiovascular Disease executive summary

By presenting a clear summary of the problem of measuring heart disease in people with diabetes, as well as real-world solutions, this new Diabetes and cardiovascular disease report facilitates evidenced-based decision making and encourages collaboration between different sectors. The primary audience for this report includes policy makers, policy implementers and diabetes advocates.

Diabetes and Cardiovascular Disease Report

By presenting a clear summary of the problem of measuring heart disease in people with diabetes, as well as real-world solutions, this new Diabetes and cardiovascular disease report facilitates evidenced-based decision making and encourages collaboration between different sectors. The primary audience for this report includes policy makers, policy implementers and diabetes advocates.